The antitumor effect of a novel differentiation inducer, 2, 2-bis (4-(4-amino-3-hydroxyphenoxy) phenyl) adamantane (DPA), in combinatory therapy on human colon cancer

International Journal of Oncology

Volumn 28, Issue 4, 2006, Pages 1003-1012

  Wang, Jane Jen ^a   Lee, Jen Yi ^a   Chen, Yu Chen ^a   Chern, Yaw Terng ^b   Chi, Chin Wen ^a,c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Adamantane derivative; Colon cancer; CPT 11; Cytostatic; Differentiation; E cadherin; p21 Cip1; p27 Kip1

Indexed keywords

2,2 BIS(4 (4 AMINO 3 HYDROXYPHENOXY)PHENYL)ADAMANTANE; 2,2-BIS(4-(4-AMINO-3-HYDROXYPHENOXY)PHENYL)ADAMANTANE; ADAMANTANE; ANTINEOPLASTIC AGENT; BETA CATENIN; CADHERIN; CADHERIN ASSOCIATED SRC SUBSTRATE P120; CADHERIN-ASSOCIATED SRC SUBSTRATE P120; CAMPTOTHECIN; CARCINOEMBRYONIC ANTIGEN; CDKN1A PROTEIN, HUMAN; CDKN1B PROTEIN, HUMAN; CELL ADHESION MOLECULE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DRUG DERIVATIVE; FIBRONECTIN; IRINOTECAN; MESSENGER RNA; PHOSPHOPROTEIN; PROTEIN P53; SIGNAL PEPTIDE;

ANIMAL; ARTICLE; BIOSYNTHESIS; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SHAPE; CELL STRAIN HT29; CELL SURVIVAL; COLON TUMOR; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; GENETICS; HUMAN; INSTITUTE FOR CANCER RESEARCH MOUSE; MALE; METABOLISM; METHODOLOGY; MOUSE; NUDE MOUSE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ADAMANTANE; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA CATENIN; BLOTTING, WESTERN; CADHERINS; CAMPTOTHECIN; CARCINOEMBRYONIC ANTIGEN; CELL ADHESION MOLECULES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SHAPE; CELL SURVIVAL; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FIBRONECTINS; G0 PHASE; G1 PHASE; HT29 CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, INBRED ICR; MICE, NUDE; PHOSPHOPROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33744736933     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.28.4.1003     Document Type: Article

References (58)

1. Aigami K, Inamoto Y, Takaishi N and Hattori K: Biologically active polycycloalkanes. 1. Antiviral adamantine derivatives. J Med Chem 18: 713-721, 1975.
2. Wang JJ, Wang SS, Lee CF, Chung MA and Chern YT: In vitro antitumor and antimicrobial activities of N-substituents of maleimide by adamantane and diamantane. Chemotherapy 43: 182-189, 1997.
3. Wang JJ, Chern YT, Liu TY and Chi CW: In vitro and in vivo growth inhibition of cancer cells by adamantylmaleimide derivatives. Anticancer Drug Des 13: 779-796, 1998.
4. Wang JJ, Chern YT, Liu TY and Chi CW: Dimethyladamantylmaleimide induced in vitro and in vivo growth inhibition of human colon cancer Colo205 cells. Anticancer Drugs 13: 533-543, 2002.
5. Wang JJ, Huang KT and Chern YT: Induction of growth inhibition and G1 arrest in human cancer cell lines by relatively low-toxic diamantine derivatives. Anticancer Drugs 15: 277-286, 2004.
6. Wang JJ, Chang YF, Chern YT and Chi CW: Study of the in vitro and in vivo effects of 1, 6-Bis[4-(4-amino-3-hydroxyphenoxy) phenyl] diamantane (DPD), a novel cytostatic and differentiation inducing agent, on human colon cancer cells. Br J Cancer 89: 1995-2003, 2003.
7. 1 arrest in human cancer cell lines by diaminophenyladamantane derivatives. Anticancer Drugs 15: 697-705, 2004.
8. Giovannucci E: Modifiable risk factors for colon cancer. Gastroenterol Clin North Am 31: 925-943, 2002.
9. Rougier P, Cutsem EV, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P and Jacques C: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352: 1407-1412, 1998. (Pubitemid 28510873)
10. Saitz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL and Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905-914, 2000.
11. Hecht JR: Gastrointestinal toxicity of irinotecan. Oncology 12: 72-78, 1998.
12. Sherr CJ: G1 phase progression: cycling on cue. Cell 79: 551-555, 1994.
13. Hunter T and Pines J: Cyclins, Cancer II. Cyclin D and CDK inhibitors come of age. Cell 79: 573-582, 1994.
14. Massague J: G1 cell-cycle control and cancer. Nature 432: 298-306, 2004.
15. Yamamoto H, Soh JW, Shirin H, Xing WQ, Lim JTE, Yao Y, Slosberg E, Tomita N, Schieren I and Weinstein IB: Comparative effects of overexpression of p27kip1 and p21cip1/waf1 on growth and differentiation in human colon carcinoma cells. Oncogene 18: 103-115, 1999.
16. Lees E: Cyclin dependent kinase regulation. Curr Opin Cell Biol 7: 773-780, 1995.
17. Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996.
18. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PAT, Ally DS, Sheahan MD, Clark WH Jr, Tuker MA and Dracopoli NC: Germline p16 mutations in familial melanoma. Nat Genet 8: 15-21, 1993.
19. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K and Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753-756, 1994.
20. Cohen E, Ophir I and Shaul YB: Induced differentiation in HT29, a human colon adenocarcinoma cell line. J Cell Sci 11: 2657-2666, 1999.
21. Fantini J, Rognoni JB, Verrier B, Lehmann M, Roccabianca M, Meauchamp J and Marvaldi J: Suramin-treated HT29-D4 cells grown in the presence of glucose in permeable culture chambers form electrically active epithelial monolayers. A comparative study with HT29-D4 cells grown in the absence of glucose. Eur J Cell Biol 51: 110-119, 1990.
22. Brattain MG, Levin A, Chakrabarty S, Yeoman I, Willson J and Long B: Heterogeneity of human colon carcinoma. Cancer Metastasis Rev 3: 177-191, 1984.
23. Drewinko B, Romsdahl MM, Yang LY, Ahearn MJ and Trujillo JM: Establishment of a human carcinoembryonic antigen-producing colon adenocarcinoma cell line. Cancer Res 36: 467-475, 1976.
24. Huang S and Chakrabarty S: Regulation of fibronectin and laminin receptor expression, fibronectin and laminin secretion in human colon cancer cells by transforming growth factor β. Int J Cancer 57: 742-746, 1994. (Pubitemid 24201369)
25. Dahl SC and Grabel LB: Integrin phosphorylation is modulated during the differentiation of F-9 teratocarcinoma stem cells. J Cell Biol 108: 183-190, 1989.
26. Lotan R, Lotan D and Carralero DM: Modulation of galactoside-binding lectins in tumor cells by differentiation inducing agents. Cancer Res 48: 115-122, 1989.
27. Vermeulen SJ, Bruyneel EA, Roy FM van, Mareel MM and Brackel ME: Activation of the E-cadherin/catenin complex in human MCF-7 breast cancer cells. Br J Cancer 72: 1447-1453, 1995.
28. Hynes RO and Lander AD: Contact and adhesive specificities in the associations, migration and targeting of cells and axons. Cell 68: 303-322, 1992.
29. Liotta LA, Steeg PS and Stetler-Stevenson WG: Cancer matastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327-336, 1991.
30. Wijnhoven BPL, Dinjens WNM and Pignatelli M: E-cadherin-catenin cell-cell adhesion complex and human cancer. Br J Surg 87: 992-1005, 2000.
31. St Croix B, Sheehan C, Rak JW, Florenes VA, Slingerland JM and Kerbel RS: E-cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27 (KIP1). J Cell Biol 142: 557-571, 1998.
32. Levenberg S, Yarden A, Kam Z and Geiger B: p27 is involved in N-cadherin-mediated contact inhibition of cell growth and S-phase entry. Oncogene 18: 869-876, 1999.
33. Nakagawa K, Sogo S, Hioki K, Tokunaga R and Taketani S: Acquisition of cell adhesion and induction of focal adhesion kinase of human colon cancer Colo 201 cells by retinoic acid-induced differentiation. Differentiation 62: 249-257, 1998.
34. Aono S, Nakagawa S, Reynolds AB and Takeichi M: p120ctn acts as inhibitory regulator of cadherin function in colon carcinoma cells. J Cell Biol 145: 551-562, 1999.
35. Ozawa M and Ohkubo T: Tyrosine phosphorylation of p120ctn in v-Src transfected L cells depends on its association with E-cadherin and reduces adhesion activity. J Cell Sci 114: 503-512, 2001.
36. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T and Wallace J: United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (2nd edition). Br J Cancer 77: 1-10, 1998.
37. Attia MA and Weiss DW: Immunology of spontaneous mammary carcinomas in mice. V. Acquired tumor resistance and enhancement in strain A mice infected with mammary tumor virus. Cancer Res 26: 1787-1800, 1966.
38. Tucker EL and Pignatelli M: Catenins and their associated proteins in colorectal cancer. Histol Histopathol 15: 251-260, 2000.
39. Nagafuchi A and Takeichi M: Cell binding function of E-cadherin is regulated by the cytoplasmic domain. EMBO J 7: 3679-3684, 1988.
40. Aho S, Levansuo L, Montonen O, Kari C, Rodeck U and Uitto J: Specific seguences in p120ctn determine subcellular distribution of its multiple isoforms involved in cellular adhesion of normal and malignant epithelial cells. J Cell Sci 115: 1391-1402, 2002.
41. Kondoh N, Schweinfest CW, Henderson KW and Papas TS: Differential expression of S19 ribosomal protein, laminin-binding protein, and human lymphocyte antigen class I messenger RNAs associated with colon carcinoma progression and differentiation. Cancer Res 52: 791-796, 1992.
42. Laferte S and Loh LC: Characterization of a family of structurally related glycoproteins expressing beta 1-6-branched asparagines-linked oligosaccharides in human colon carcinoma cells. Biochem J 283: 193-201, 1992.
43. Stein U, Walther W and Shoemaker RH: Modulation of mdr1 expression by cytokines in human colon carcinoma cells: an approach for reversal of multidrug resistance. Br J Cancer 74: 1384-1391, 1996. (Pubitemid 26370728)
44. Schroder C, Eckert K and Maurer HR: Tributyrin induces growth inhibitory and differentiating effects on HT-29 colon cancer cells in vitro. Int J Oncol 13: 1335-1340, 1998.
45. Tanaka Y, Bush KK, Eguchi T, Ikekawa N, Taguchi T, Kobayashi Y and Higgins PJ: Effect of 1, 25-dihydroxyvitamin D3 and its analogs on butyrate-induced differentiation of HT-29 human colonic carcinoma cells and on the reversal of the differentiated phenotype. Arch Biochem Biophys 276: 415-423, 1990.
46. Reynolds S, Rajagopal S and Chakrabarty S: Differentiation-inducing effect of retinoic acid, difluoromethylornithine, sodium butyrate and sodium suramine in human colon cancer cells, Cancer Lett 134: 53-60, 1998.
47. Wang Y, Cheong D, Chan S and Hooi SC: Heparin/Heparan sulfate interacting protein gene expression is up-regulated in human colorectal carcinoma and correlated with differentiation status and metastasis. Cancer Res 59: 2989-2994, 1999.
48. Velcich A, Palumbo L, Jarry A, Laboisse C, Racevskis J and Augenlicht L: Patterns of expression of lineage-specific markers during the in vitro-induced differentiation of HT-29 colon carcinoma cells. Cell Growth Differ 6: 749-757, 1995.
49. Ohannesian D, Lotan D and Lotan R: Concomitant increases in galectin-1 and its glycoconjugate ligands (carcinoembryonic antigen, lamp-1 and lamp-2) in cultured human colon carcinoma cells by sodium butyrate, Cancer Res 54: 5992-6000, 1994.
50. Niles R, Wilhelm S, Thomas P and Zamcheck N: The effects of sodium butyrate and retinoic acid on cell growth and CEA production in a series of human colorectal tumor cell lines representing different states of differentiation. Cancer Invest 6: 39-45, 1988.
51. Ophir I, Cohen E and Ben-Shaul Y: Apical polarity in human colon carcinoma cell lines. Tissue Cell 27: 659-666, 1995.
52. Bates S and Vousden KH: p53 in signaling checkpoint arrest and apoptosis. Curr Opin Genet Dev 6: 1-7, 1996.
53. Waldman T, Kinzleer KW and Vogelstein B: p21 is necessary for the p53-mediated G1 arrest in human cancer cell. Cancer Res 55: 5187-5190, 1995.
54. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM, Kaushansky K and Robert JM: A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis and female sterility in p27/kip1-deficient mice. Cell 85: 733-744, 1996.
55. Pignatelli M, Liu D, Nasin MN, Stamp VH, Hirano S and Takeichi M: Morphoregulator activities of E-cadherin and beta-1 integrins in colorectal tumor cells. Br J Cancer 66: 629-634, 1992.
56. Mann B, Gelos M, Siedow A, Hanski ML, Gratchev A, Ilyas M, Bodmer WF, Moyer MP, Riecken EO, Buhr HJ and Hanski C: Target genes of beta-catenin-T cell-factor/lymphoid-enhancerfactor signaling in human colorectal carcinomas. Proc Natl Acad Sci USA 96: 1603-1608, 1999.
57. Tetsu O and McCormick F: Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398: 422-426, 1999.
58. cas isoforms and heterogeneous expression of p120cas isoforms in human tumor cell lines. Cancer Res 56: 2633-2640, 1996.